Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Axsome Therapeutics stock has risen 16% year-to-date. Analysts predict a 37% upside based on average price targets. The company has seen significant clinical and regulatory progress, including approval for Auvelity and Sunosi.
Intelligence analysis by Qwen 2.5 (3B)
Axsome Therapeutics stock has performed well, with a 16% year-to-date increase. Analysts predict a 37% upside based on average price targets. The company has seen significant clinical and regulatory progress, including approval for Auvelity and Sunosi.
Axsome Therapeutics is a company that makes medicine for people who are sick. They've made some new medicines that help people feel better. The company is doing well and people think it will do even better in the future. So they're buying the company's stock.
Analysis
Axsome Therapeutics' Clinical and Regulatory Progress
Axsome Therapeutics has made significant clinical and regulatory progress over the past few years. The company earned approval for Auvelity as a treatment for depression, and more recently won a label expansion for the medicine in treating Alzheimer's disease (AD) agitation. Auvelity is the main growth driver, contributing $180.3 million in net product sales in the second quarter, up 51% compared to the year-ago period.
Axsome Therapeutics' Pipeline
Axsome Therapeutics boasts a rich lineup of mid and late-stage candidates that could transform its approved portfolio over the next few years. Some of these products include AXS-12, AXS-14, and AXS-20. The company estimates that these products could generate peak sales above $16 billion.
Wall Street's Outlook
Wall Street is bullish on Axsome Therapeutics, with analysts predicting a 37% upside based on average price targets. The company's market cap is expected to grow at a compound annual rate of 11.1% over the next 14 years, which is a strong return.
Key points
- Axsome Therapeutics has seen significant clinical and regulatory progress, including approval for Auvelity and Sunosi.
- The company's pipeline of products could generate peak sales above $16 billion.
- Analysts predict a 37% upside based on average price targets.
Axsome Therapeutics could see significant revenue growth from its pipeline of products, leading to a substantial increase in its market cap. The company's market cap is expected to grow at a compound annual rate of 11.1% over the next 14 years.
Axsome Therapeutics may face clinical setbacks or stronger competition in markets where it currently performs well, such as depression treatments. These factors could negatively impact the company's financial performance.
